Literature DB >> 16533964

LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Carles Gaig1, Mario Ezquerra, Maria Jose Marti, Esteban Muñoz, Francesc Valldeoriola, Eduardo Tolosa.   

Abstract

BACKGROUND: Several pathogenic mutations in the LRRK2 gene have been implicated in familial and sporadic cases of Parkinson disease (PD). The R1441G mutation is frequent in Spanish patients of Basque ethnicity with PD, and the G2019S mutation is a common mutation found in several populations worldwide.
OBJECTIVES: To determine the frequency of the LRRK2 G2019S and R1441G mutations in PD patients from the non-Basque northeast region of Spain (Catalonia), and to characterize their family history and clinical features.
DESIGN: We screened patients for the presence of the LRRK2 R1441G and G2019S mutations. These LRRK2 mutations were detected by restriction endonuclease digestion, and samples with an abnormal electrophoresis pattern were sequenced to identify the exact nucleotide change. The clinical features and family history of patients with LRRK2 mutations were studied in detail.
SETTING: The northeast region of Spain. Patients Three hundred two patients with PD. MAIN OUTCOME MEASURES: Onset age, clinical features, and family history of PD and LRRK2 mutations.
RESULTS: The R1441G mutation was present in 0.7% of total PD cases. The G2019S mutation was found in 6.4% of familial and 3.4% of sporadic cases. Additionally, we found 1 patient with the R1441C mutation. Age at onset ranged from 33 to 78 years. Clinical features were not different from classic PD, except for 1 patient who presented with monosymptomatic leg rest tremor of 8 years' duration. In addition, a 91-year-old unaffected relative of a patient with the G2019S mutation was found to be a mutation carrier.
CONCLUSIONS: The G2019S mutation frequency in PD patients from northeast Spain is similar to that reported in other European regions. The R1441G mutation is very uncommon in Catalonia. The presence of an aged unaffected G2019S mutation carrier supports the previously described occurrence of incomplete penetrance in PD patients with LRRK2 mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533964     DOI: 10.1001/archneur.63.3.377

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  37 in total

1.  Age at onset in LRRK2-associated PD is modified by SNCA variants.

Authors:  Teresa Botta-Orfila; Mario Ezquerra; Pau Pastor; Rubén Fernández-Santiago; Claustre Pont-Sunyer; Yaroslau Compta; Oswaldo Lorenzo-Betancor; Lluis Samaranch; Maria José Martí; Francesc Valldeoriola; Matilde Calopa; Manel Fernández; Miquel Aguilar; Oriol de Fabregas; Jorge Hernández-Vara; Eduard Tolosa
Journal:  J Mol Neurosci       Date:  2012-06-06       Impact factor: 3.444

Review 2.  The pleomorphic pathology of inherited Parkinson's disease: lessons from LRRK2.

Authors:  Vincenzo Bonifati
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

Review 3.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 4.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

5.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Adriana Cardozo; Maria Jesus Rey; Eduardo Tolosa
Journal:  BMJ Case Rep       Date:  2009-01-23

6.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Maria Jesús Rey; Adriana Cardozo; Eduardo Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-08       Impact factor: 10.154

7.  Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.

Authors:  A S Chen-Plotkin; W Yuan; C Anderson; E McCarty Wood; H I Hurtig; C M Clark; B L Miller; V M-Y Lee; J Q Trojanowski; M Grossman; V M Van Deerlin
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

8.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Authors:  K Haugarvoll; R Rademakers; J M Kachergus; K Nuytemans; O A Ross; J M Gibson; E-K Tan; C Gaig; E Tolosa; S Goldwurm; M Guidi; G Riboldazzi; L Brown; U Walter; R Benecke; D Berg; T Gasser; J Theuns; P Pals; P Cras; P Paul De Deyn; S Engelborghs; B Pickut; R J Uitti; T Foroud; W C Nichols; J Hagenah; C Klein; A Samii; C P Zabetian; V Bonifati; C Van Broeckhoven; M J Farrer; Z K Wszolek
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

9.  Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.

Authors:  Carolina Perez-Pastene; Stephanie A Cobb; Fernando Díaz-Grez; Mary M Hulihan; Marcelo Miranda; Pablo Venegas; Osvaldo Trujillo Godoy; Jennifer M Kachergus; Owen A Ross; Luis Layson; Matthew J Farrer; Juan Segura-Aguilar
Journal:  Neurosci Lett       Date:  2007-06-17       Impact factor: 3.046

Review 10.  LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.

Authors:  Vincenzo Bonifati
Journal:  Neurochem Res       Date:  2007-04-18       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.